Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Presidential symposium 3

1557O - Adaptive immunity to SARS-CoV-2 infection and vaccination in cancer patients: The CAPTURE study


20 Sep 2021


Presidential symposium 3


Scott Shepherd


Annals of Oncology (2021) 32 (suppl_5): S1129-S1163. 10.1016/annonc/annonc713


S.T.C. Shepherd1, A. Fendler2, L. Au2, F. Byrne2, K. Wilkinson3, M. Wu4, A.M. Schmitt5, N. Joharatnam-Hogan5, B. Shum5, L. Del Rosario5, K. Edmonds1, E. Carlyle1, E. Nicholson6, M. Howell4, C. Swanton7, S. Walker8, G. Kassiotis9, R. Wilkinson3, J. Larkin10, S. Turajlic2

Author affiliations

  • 1 The Renal & Skin Unit, The Royal Marsden Hospital - NHS Foundation Trust, SW3 6JJ - London/GB
  • 2 Cancer Dynamics Laboratory, The Francis Crick Institute, NW1 1AT - London/GB
  • 3 Tuberculosis Laboratory, The Francis Crick Institute, NW1 1AT - London/GB
  • 4 High Throughput Screening, The Francis Crick Institute, NW1 1AT - London/GB
  • 5 Medical Oncology, The Royal Marsden Hospital - NHS Foundation Trust, SW3 6JJ - London/GB
  • 6 Haemato-oncology, The Royal Marsden Hospital - NHS Foundation Trust, SW3 6JJ - London/GB
  • 7 N/a, Francis Crick Institute, NW1 1AT - London/GB
  • 8 Department Of Anaesthesia And Critical Care, The Royal Marsden Hospital - NHS Foundation Trust, SW3 6JJ - London/GB
  • 9 Retroviral Immunology Laboratory, The Francis Crick Institute, NW1 1AT - London/GB
  • 10 Medicine, Royal Marsden Hospital NHS Foundation Trust, SW3 6JJ - London/GB


Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 1557O


Patients with cancer are at increased risk of severe outcomes from COVID-19. Understanding the impact of SARS-CoV-2 infection and vaccination induced-immunity is an area of unmet need.


CAPTURE (NCT03226886) is a prospective longitudinal cohort study of COVID-19 vaccine or SARS-CoV-2 infection-induced immunity. SARS-CoV-2 infections were confirmed by RT-PCR and ELISA. Neutralising antibody titres (NAbT) against wild-type (WT) SARS-CoV-2 and variants of concern (VOC; Alpha, Beta, Delta) and SARS-CoV-2 specific T-cells (SsT-cells) were quantified.


118 patients (89% solid malignancy, [SM]) were SARS-CoV-2-positive (median follow-up: 154 days). 85% patients were symptomatic; 2 died of COVID-19. 82% had S1-reactive antibodies, of whom 89% had neutralising antibodies (NAbs); NAbT were lower against all VOCs. While S1-reactive antibody levels declined over time, NAbT remained stable up to 329 days. Most patients had detectable SsT-cells (76% CD4+, 52% CD8+). Haematological malignancy (HM) patients had impaired immune responses that were disease and treatment-specific (anti-CD20), but with evidence suggestive of compensation from T-cells. 585 patients were evaluated following 2 doses of BNT162b2 or AZD1222 vaccines, administered 12 weeks apart. Seroconversion rates after 2 doses were 85% and 54% in patients with SM and HM, respectively. A lower proportion of patients had detectable NAbs against SARS-CoV-2 VOC (Alpha 62%, Beta 54%, Delta 49%) vs WT (84%), with corresponding significantly lower NAbT. Patients with HM were more likely to have an undetectable NAb and had lower NAbT vs solid malignancies to both WT and VOCs. Seroconversion showed poor concordance with NAbTs against VOCs. Prior SARS-CoV-2 infection boosted NAbT including against VOCs. Anti-CD20 treatment was associated with severely diminished NAbTs. Vaccine-induced T-cell responses were detected in 80% of patients, with no differences between vaccines or cancer types.


Patients with HM had blunted humoural responses to infection and vaccination, particularly against VOCs, but preserved cellular responses might contribute to protection. Our results lend support to prioritisation of all cancer patients for further booster vaccination.

Clinical trial identification


Editorial acknowledgement

Legal entity responsible for the study

The Royal Marsden NHS Foundation Trust.


The Royal Marsden Charity; The National Institute for Health Research (NIHR) Biomedical Research Centre (BRC) at the Royal Marsden Hospital and Institute for Cancer Research (ICR).


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.